Track topics on Twitter Track topics that are important to you
SALT LAKE CITY, March 02, 2017 (GLOBE NEWSWIRE) -- Great Basin Scientific, Inc. (OTCQB:GBSN), a molecular diagnostics company, announced today that Dr. Suzette Chance, senior director of regulatory and clinical affairs, has won a 2017 Women Worth Watching® in STEM Award by Profiles in Diversity Journal. The publication is dedicated to promoting and advancing diversity and inclusion in the corporate, government, nonprofit, STEM, and higher education sectors. Dr. Chance was one of 45 women nationwide to receive the award, which is an expansion of the publication’s annual Women Worth Watching leadership awards program.
“In the short time since Suzette joined Great Basin, she has shepherded the clinical trials and FDA submissions for our last three assays – one of which is now commercially available, with two others awaiting FDA clearance – a feat that is nothing short of remarkable,” said Rob Jenison, senior vice president, R&D and chief technology officer of Great Basin Scientific. “Her professionalism, commitment to quality and prior success in running clinical trials has had a tangible impact on the Company’s success in accelerating the build-out of our product menu. We are so pleased to have Suzette on our team and congratulate her on this well-earned recognition.”
Dr. Chance joined Great Basin in February 2016 with over 20 years of experience in in vitro diagnostics, working with clinical and regulatory affairs and product innovation and design. Prior to joining Great Basin, she served senior leadership roles with Immucor GTI Diagnostics, Gen-Probe/Hologic, and Genetic Testing Institute. Dr. Chance started her career as a scientist and biochemist with DuPont Medical Products in Glasgow, where she created and established a new bio-analytical laboratory for the DuPont facility. She earned her B.S. degree in biochemistry at the University of Minnesota, her Ph.D. in biochemistry at Johns Hopkins University, School of Hygiene and Public Health, and completed a post-doctoral fellowship at Johns Hopkins University, Department of Cell Biology and Anatomy. Dr. Chance has been involved in the development of three patents and has co-authored 13 published papers.
Speaking about diversity in STEM fields, Dr. Chance said, “Diversity across STEM industries is paramount in driving innovation and advancement. While women remain underrepresented in STEM industries, particularly in leadership roles, recognitions like this shed light on the many successful women who are making a difference, and hopefully inspire a younger generation of women to pursue their own rewarding careers in these important fields. I’m pleased to be part of an organization like Great Basin that values diversity, and am honored to be included in the first group of women recognized by Profiles in Diversity Journal for contributing to the advancement of STEM.”
Dr. Chance will be profiled in a special STEM Women Worth Watching edition issued in April 2017. To view the publication’s press release and a full list of this year’s award winners, click here.
About Great Basin Scientific
Great Basin Scientific is a molecular diagnostics company that commercializes breakthrough chip-based technologies. The Company is dedicated to the development of simple, yet powerful, sample-to-result technology and products that provide fast, multiple-pathogen diagnoses of infectious diseases. The Company’s vision is to make molecular diagnostic testing so simple and cost-effective that every patient will be tested for every serious infection, reducing misdiagnoses and significantly limiting the spread of infectious disease. More information can be found on the company’s website at www.gbscience.com.
This press release includes forward-looking statements regarding events, trends, and business prospects, which may affect our future operating results and financial position, including but not limited to statements regarding the Company’s anticipated FDA approval of current pending assays, commercialization of future approved assays, and the Company’s general development plans of sample-to-result technology and products. Forward-looking statements involve risks and uncertainties, which could cause actual results to differ materially, and reported results, should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: the assumptions of management in the revenue projections not occurring as anticipated, delay or denial in obtaining FDA approval of pending assays, uncertainty in the Company’s ability to commercialize new assays, changes in customer needs, competition in the industry being greater than anticipated, our limited operating history and history of losses; our ability to develop and commercialize new products and the timing of commercialization; our ability to obtain sufficient capital to continue as a going concern and implement our business plan; and other risks set forth in the Company’s filings with the Securities and Exchange Commission, including the risks set forth in the Company’s Annual Report on Form 10-K for the year ended December 31, 2015 and Quarterly Report on Form 10-Q for the quarter ended September 30, 2016. These forward-looking statements speak only as of the date hereof, and Great Basin Scientific specifically disclaims any obligation to update these forward-looking statements, except as required by law.
Contact: Betsy Hartman Great Basin Scientific 385.215.3372 firstname.lastname@example.orgNEXT ARTICLE
A diagnostic test is any kind of medical test performed to aid in the diagnosis or detection of disease. For example: to diagnose diseases to measure the progress or recovery from disease to confirm that a person is free from disease Clin...
Women's Health - key topics include breast cancer, pregnancy, menopause, stroke Follow and track Women's Health News on BioPortfolio: Women's Health News RSS Women'...
Clinical trials are a set of procedures in medical research conducted to allow safety (or more specifically, information about adverse drug reactions and adverse effects of other treatments) and efficacy data to be collected for health interventions (e.g...